Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | CBL |
| Variant | mutant |
| Impact List | unknown |
| Protein Effect | unknown |
| Gene Variant Descriptions | CBL mutant indicates an unspecified mutation in the CBL gene. |
| Associated Drug Resistance | |
| Category Variants Paths |
CBL mutant |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05441514 | Phase I | Cobimetinib + Enasidenib | Enasidenib in Combination With Cobimetinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia | Active, not recruiting | USA | 0 |
| NCT06297629 | Phase II | Decitabine and Cedazuridine | A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell Transplantation | Withdrawn | USA | 0 |
| NCT05849662 | Phase Ib/II | Azacitidine + Cytarabine + Fludarabine + Trametinib Azacitidine + Trametinib | A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia | Recruiting | USA | 0 |
| NCT03190915 | Phase II | Trametinib | Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia | Active, not recruiting | USA | 0 |
| NCT05365035 | Phase II | Azacitidine + Venetoclax Cladribine + Cytarabine + Venetoclax | A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts | Recruiting | USA | 0 |
| NCT06504459 | Phase II | Cladribine + Cytarabine + Venetoclax Azacitidine + Venetoclax | Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML | Recruiting | USA | 0 |
| NCT03613532 | Phase I | Azacitidine + Venetoclax Busulfan + Fludarabine + Venetoclax Decitabine and Cedazuridine | Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN | Active, not recruiting | USA | 0 |
| NCT04409639 | Phase II | Cobimetinib | Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway Mutations (CONCERTO) | Recruiting | USA | 0 |
| NCT04708054 | Phase II | Busulfan + Cladribine + Fludarabine + Thiotepa + Venetoclax | Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS | Recruiting | USA | 0 |